Gemini Therapeutics, Inc. engages in developing therapeutic compounds for treating genetically defined age-related macular degeneration (AMD)Its lead candidate is GEM103, a recombinant form of the human complement factor H protein. The company also develops GEM307 for treatment of systemic diseases.